A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Latest Information Update: 02 Jul 2024
At a glance
- Drugs HFB 200301 (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Gastric cancer; Germ cell cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Testicular cancer
- Focus Adverse reactions; First in man
- Sponsors HiFiBiO
- 04 Jun 2024 Initial results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 30 Apr 2024 According to a HiFiBiO Therapeutics media release, data from this study will be presented in the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), set for May 31-June 4, 2024, in Chicago, IL.
- 14 Dec 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.